These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29171913)

  • 21. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G-CSF filgrastim biosimilar-Sandoz reduces the incidence of febrile neutropenia in patients receiving chemotherapy regimens with rest periods not exceeding 14 days: A French, multicenter, prospective, non-interventional study.
    Phelip JM; Souquet PJ; Hacini M; Chehimi M; Bourgeois V; Bennoune R; Tredan O
    Cancer Treat Res Commun; 2023; 35():100690. PubMed ID: 36780734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
    Kim DY; Nam J; Chung JS; Jeon BE; Lee JH; Jo JC; Kim SW; Shin HJ
    Cancer Res Treat; 2022 Oct; 54(4):1256-1267. PubMed ID: 34990523
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer.
    Sagara Y; Sato K; Fukuma E; Higaki K; Mizutani M; Osaki A; Takano T; Tokuda Y; Ohno S; Masuda N; Suzuki M; Saeki T
    Jpn J Clin Oncol; 2013 Sep; 43(9):865-73. PubMed ID: 23858037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.
    Blackwell K; Semiglazov V; Krasnozhon D; Davidenko I; Nelyubina L; Nakov R; Stiegler G; Singh P; Schwebig A; Kramer S; Harbeck N
    Ann Oncol; 2015 Sep; 26(9):1948-1953. PubMed ID: 26122726
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
    McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
    J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
    [No Abstract]   [Full Text] [Related]  

  • 27. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
    Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
    Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
    Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Guidance on the Prescription Patterns of G-CSFs for the Prevention of Febrile Neutropenia Following Anticancer Chemotherapy: A Population-Based Utilization Study in the Lazio Region.
    Trotta F; Mayer F; Mecozzi A; Amato L; Addis A
    BioDrugs; 2017 Apr; 31(2):117-124. PubMed ID: 28353170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
    Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
    J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices.
    Rifkin RM; Crawford J; Mahtani RL; Dale DC; Narang M; MacLaughlin WW; Huynh C; Gawade PL; Lewis S; DeCosta L; Lawrence T; Belani R
    Support Care Cancer; 2022 Oct; 30(10):7913-7922. PubMed ID: 35732748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated With Chemotherapy for Lymphoid Malignancies.
    Damaj GL; Benbrahim O; Hacini M; Voronina I; Benabed K; Soumoudronga RF; Gasnereau I; Haioun C; Solal-Céligny P
    Clin Lymphoma Myeloma Leuk; 2017 Jun; 17(6):362-369.e2. PubMed ID: 28622961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mecapegfilgrastim for prophylaxis of febrile neutropenia in children and adolescents with rhabdomyosarcoma or Ewing sarcoma: a prospective, single-arm, pilot study.
    Zhao W; Zhou Y; Wang X; Yang P; Huang C; Ma X; Su Y; Zhang R
    BMC Cancer; 2024 Aug; 24(1):1013. PubMed ID: 39148050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
    Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
    J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the safety and effectiveness of PegaGen
    Jenabian A; Ehsanpour A; Mortazavizadeh SMR; Raafat J; Razavi M; Khosravi A; Seifi S; Salimi B; Anjidani N; Kafi H
    Support Care Cancer; 2022 Oct; 30(10):8151-8158. PubMed ID: 35792924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim.
    Lee M; Yee J; Kim JY; Kim JY; An SH; Lee KE; Gwak HS
    Asia Pac J Clin Oncol; 2019 Aug; 15(4):231-237. PubMed ID: 30997742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.
    Jeong SH; Kim SJ; Yoon DH; Park Y; Kang HJ; Koh Y; Lee GW; Lee WS; Yang DH; Do YR; Kim MK; Yoo KH; Choi YS; Yun HJ; Yi JH; Jo JC; Eom HS; Kwak JY; Shin HJ; Park BB; Hyun SY; Yi SY; Kwon JH; Oh SY; Kim HJ; Sohn BS; Won JH; Kim SH; Lee HS; Suh C; Kim WS
    Cancer Res Treat; 2022 Oct; 54(4):1268-1277. PubMed ID: 34990525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
    Clemons M; Fergusson D; Simos D; Mates M; Robinson A; Califaretti N; Zibdawi L; Bahl M; Raphael J; Ibrahim MFK; Fernandes R; Pitre L; Aseyev O; Stober C; Vandermeer L; Saunders D; Hutton B; Mallick R; Pond GR; Awan A; Hilton J
    Ann Oncol; 2020 Jul; 31(7):951-957. PubMed ID: 32325257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.